ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Joachim Eeckhout contributed 195 entries already.
Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule pipeline in endocrinology and immunology, including a potential treatment for congenital adrenal hyperplasia that will compete with drugs developed by Vertex and Neurocrine Biosciences.
BioNTech’s BNT113, combined with Keytruda, failed to significantly improve progression-free survival in a Phase 2/3 head and neck cancer trial. The study will continue to assess whether the combination helps patients live longer.
Zealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and other metabolic diseases, broadening its pipeline beyond peptides and small molecules.
AATec is advancing ATL-105, a new recombinant version of alpha-1 antitrypsin for inhalation, into clinical development for chronic respiratory diseases. Rüdiger Jankowsky, CEO, and Gabriele Matschiner, Chief Development Officer, explain the development program, the choice of bronchiectasis and the upcoming Phase 1b/2a trial.
Beyond the main headlines, European biotech kept moving this week. Lundbeck and Neurosterix advanced neurological drug programs, Rewind secured funding for myelin repair, and Beactica selected a cancer degrader. Plus, new findings from iOnctura and Coave. Here’s your weekly catch-up.
Undecimal Bio has launched with $18 million (about €16 million) in seed funding to develop delivery molecules that carry gene-silencing medicines beyond the liver, initially targeting kidney and vascular tissues.
Roche has licensed worldwide rights to Rona Therapeutics’ experimental ALK7-targeting RNA interference therapy for obesity and metabolic diseases, offering up to $100 million (about €89 million) in upfront and near-term payments, plus up to $1.06 billion (about €0.95 billion) in milestone payments.
Swedish biotech Elicera Therapeutics reported complete metabolic responses in eight of 12 patients treated with its experimental CAR-T therapy ELC-301 in the Phase 1 portion of its CARMA trial. Six remained in complete response at their latest assessment.
Finnish biotech Desentum has raised €28 million in an oversubscribed equity round to advance three allergy immunotherapy programs, with Phase 2 results for its lead birch pollen candidate expected before year-end.
Perfusion is here, and it is rewriting the rules of biologics and biosimilar manufacturing. What was once experimental has become industrial reality: scalable, robust, regulatorily accepted, and commercially proven. As global demand for high quality, cost competitive biosimilars accelerates, perfusion stands ready as the technology built for this moment.